obstructive pulmonary disease
Recently Published Documents


TOTAL DOCUMENTS

31207
(FIVE YEARS 13210)

H-INDEX

225
(FIVE YEARS 52)

2022 ◽  
Vol 12 (4) ◽  
pp. 739-746
Author(s):  
Zhihong Qiu ◽  
Li Yan ◽  
Juan Xu ◽  
Xiaojun Qian

Objective: The aim of our research was to evaluate Nrf2 in COPD treatment and relative mechanism by vivo study. Materials: The mice were divided into Normal, Model and CCL16 groups. Measuring Pathology and goblet cell number by HE or AB/PAS staining; Evaluating apoptosis cell number by TUNEL assay; using flow separation to analysis inflammatory cells in difference groups; MAPK and NF-κB(p65) protein expression were evaluated by IHC assay in tissues; Total protein concentration of MUC5AC, Nrf2, Bax and Bcl-2 were evaluated by WB assay. Results: Compared with Normal group, the pathology was deteriorate and goblet cell number were significantly up-regulation in Model group, apoptosis goblet cell number were significantly depressed (P < 0.001), lympbocyte rate and hypertrophic rate were significantly down-regulation and Eosinophils rate, Macrophage rate and Neutrophils rate were significantly up-regulation (P < 0.001, respectively) in Model group. By IHC assay, MAPK and NF-κB(p65) proteins expression significantly increased (P < 0.001, respectively) in Model group; by WB assay, MUC5AC and Bcl-2 protein expression were significantly up-regulation and Nrf2 and Bax proteins expression were significantly down-regulation (P < 0.001, respectively) in Model group. Nrf2 supplement, the COPD were significantly improved with relative inflammatory cells rates significantly improving and relative proteins improving. Conclusion: Nrf2 could improve COPD by inducing goblet cell apoptosis increasing via regulation MAPK/NF-κB(p65) pathway in vivo study.


2022 ◽  
Vol 65 (5) ◽  
pp. 101587
Author(s):  
Thamyres Spositon ◽  
Joice M. Oliveira ◽  
Antenor Rodrigues ◽  
Jéssica Fonseca ◽  
Lais Santin ◽  
...  

2022 ◽  
Vol 28 (1) ◽  
pp. 17-19
Author(s):  
Guangheng Wang ◽  
Yuqi Cai

ABSTRACT Introduction: Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by incomplete reversibility of airflow obstruction and persistent respiratory symptoms. Objective: To explore the therapeutic effect of physical exercise on patients with chronic obstructive pulmonary disease in pulmonary rehabilitation. Methods: Forty-eight experimental subjects were divided into control group, experimental group 1, and experimental group 2 for research. The control group received normal medical-related treatment without any other means of intervention. In addition to normal medical-related treatment, experimental group 1 received breathing training and educational interventions and experimental group 2 received exercise, breathing training and educational interventions. Results: The vital capacity of female subjects before and during the experiment ranged from 2.23±0.01 to 2.26±0.04, the FVC ranged from 2.00±0.02 to 2.01±0.03, the FEV1 ranged from 1.03±0.01 to 1.03±0.01,the FEV1% ranged from 55.50±1.29 to 55.25±1.71,the FEV1/FVC ranged from 51.44±0.24 to 50.84±1.00, andthe heart rate ranges from 65.00±0.82 to 65.50±1.29. Conclusions: Exercise training can increase the exercise tolerance of patients with COPD, relieve dyspnea, and improve the quality of life. Level of evidence II; Therapeutic studies - investigation of treatment results.


2022 ◽  
Vol 12 (3) ◽  
pp. 641-646
Author(s):  
Minna Wu ◽  
Bo Xu

We aimed to explore the efficacy of bone marrow mesenchymal stem cell (BMSC) transplantation combined with nasal continuous positive airway pressure (nCPAP) for treating severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD). SD rat AECOPD model was established by injecting endotoxin and Staphylococcus aureus and then treated with nCPAP, BMSCs, or nCPAP combined with BMSCs (n = 20) and their conditions were evaluated with BBB score at 1 d, 3 d, 7 d, 14 d, 28 d after treatment along with analysis of apoptosis and BrdU-positive cells as well as NF200 expression by TUNEL kit staining and levels of Th1, Th7 and Th12 before and after treatment. As revealed by BBB score and HE staining, all treatments significantly alleviated the symptom of severe APEOPD (p < 0.05), while compared with nCPAP, the combined treatment exhibited higher efficacy. Besides, upon treatment, apoptosis and level of Th1, Th7 and Th12 was reduced but N200 absorbance value was elevated, with significant difference in combination group (p < 0.05). In conclusion, BMSC transplantation in combination with nCPAP alleviates severe AECOPD by reducing cell apoptosis, repairing cell damage, and regulating T-cell subsets.


Sign in / Sign up

Export Citation Format

Share Document